The NIDDK Disorders of Gastrointestinal Interoception Consortium (DGIC) – Clinical Research Centers (U01 Clinical Trial Not Allowed) (USA)

National Institutes of Health (NIH)

The NIDDK Disorders of Gastrointestinal Interoception Consortium (DGIC) – Clinical Research Centers (U01 Clinical Trial Not Allowed) funding opportunity from the National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), supports Clinical Research Centers that will join a consortium studying gastrointestinal motility disorders in adults and children.

The consortium aims to identify the mechanisms linking altered gastrointestinal interoception to dysmotility and patient symptoms, to find disease or response biomarkers, and to use state-of-the-art technologies to identify novel therapeutic targets for future clinical trials.

Applications are open to organizations, for-profit companies, and government entities based in the United States. Applicants must document their ability to recruit and enroll patients with a motility disorder and address at least two of the three consortium goals. Clinical trials or work limited to animal models or in vitro studies are not supported.

Application budgets are limited to 500,000 USD in direct costs per year. The maximum project period is 5 years.

Opportunity number: RFA-DK-28-213

Applications open on January 5, 2027, and close on February 5, 2027.